Hcmed Innovations Co

Hcmed Innovations Co Tangible Book Value per Share

The Tangible Book Value per Share of Hcmed Innovations Co (6934.TWO) as of Nov 6, 2026 is 8.80 TWD. In the previous year, Tangible Book Value per Share was 5.98 TWD — a change of 47.09% (higher).

Tangible Book Value per Share

8.80TWD

YoY

47.09%

Last updated:

Tangible Book Value per Share of Hcmed Innovations Co is 2025 8.80 TWD. Tangible Book Value per Share of Hcmed Innovations Co was 2024 5.98 TWD. It decreases by 47.09% higher compared to the previous year.

The Hcmed Innovations Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2020
-4.46 TWD
Jan 1, 2021
-5.27 TWD
Jan 1, 2022
2.67 TWD
Jan 1, 2023
7.11 TWD
Jan 1, 2024
5.98 TWD
Jan 1, 2025
8.80 TWD
The Hcmed Innovations Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
8.80TWD+47.09%
5.98TWD-15.89%
7.11TWD+165.85%
2.67TWD-150.71%
-5.27TWD+18.21%
-4.46TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hcmed Innovations Co Stock analysis

What does Hcmed Innovations Co do? Hcmed Innovations Co Ltd generates revenue through the design, development, production, and sales of handheld medical nebulizers tailored to pharmaceutical companies' requirements. The company offers vibrating mesh nebulizers that adjust oscillation frequency for effective drug delivery to the lower respiratory tract without specialized breathing techniques, targeting conditions like chronic obstructive pulmonary disease, asthma, cystic fibrosis, and respiratory infections. Additionally, Hcmed provides contract development and manufacturing organization (CDMO) services for drug-specific nebulizers, focusing on inhalation dosage form design and development. Key markets include the United States, Taiwan, Switzerland, Israel, and the United Kingdom, where pharmaceutical companies purchase these specialized medical devices and services. The company's primary products are vibrating mesh nebulizers and CDMO services for pharmaceutical clients. Vibrating mesh nebulizers are designed to deliver medications efficiently to the respiratory system, while CDMO services support the creation of nebulizers optimized for specific drugs. These offerings are sold to pharmaceutical companies seeking to enhance their inhalation therapy solutions. The United States, Taiwan, Switzerland, Israel, and the United Kingdom represent the main geographic segments driving sales, with pharmaceutical firms as the core customer base. Hcmed Innovations Co Ltd monetizes its expertise in medical device development by supplying both hardware and specialized manufacturing services. The vibrating mesh nebulizer technology enables precise drug delivery, addressing high-demand respiratory conditions. CDMO services further capitalize on the growing need for customized inhalation therapies, with pharmaceutical companies as the primary buyers. Sales are concentrated in the United States, Taiwan, Switzerland, Israel, and the United Kingdom, reflecting the global reach of its target market. Hcmed Innovations Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hcmed Innovations Co stock

Tangible Book Value per Share of Hcmed Innovations Co is 8.80 TWD in 2025.

Tangible Book Value per Share of Hcmed Innovations Co changed from 5.98 TWD to 8.80 TWD, representing a 47.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Hcmed Innovations Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hcmed Innovations Co

All Key Metrics — Hcmed Innovations Co